title: The risk of malignancy or progression of existing malignancy in patients with psoriasis treated with biologics: case report and review of the literature.
abstract: There is some debate regarding the risk of developing malignancy and progression of malignancy in patients with psoriasis treated with biologics. The lack of extensive, long-term, and large studies, including patients with psoriasis, to assess these aforementioned risks makes it difficult to ascertain the safety profile of biologic therapy in these patients. Several studies do support the favorability of the safety profile of biologics in patients with psoriasis in terms of the risk of developing malignancy. A few studies include patients with a previous history of cancer that were thereafter treated with biologics and show no increased risk of recurrence in those treated with biologics compared to non-biologic therapy. Although recent studies do not show an increased risk of new or recurrent malignancy in patients with psoriasis treated with biologic agents, there is still hesitancy in the widespread use of biologic agents in these patients. Considering all of the current data and opinions, the benefits of biologic therapy to improve quality of life often outweigh the negligible risk of solid organ malignancy associated with biologics in patients with existing or previous malignancies. Coordinating the management of patients that develop or have a history of previous malignancy with an oncology team is crucial for patient-centered care until clear evidence-based guidelines are developed.
authors.affiliation: Department of Dermatology & Cutaneous Surgery, University of Miami, Miami, FL, USA.
authors.forename: Shailee
authors.initials: S
authors.lastname: Patel
authors.affiliation: Department of Dermatology & Cutaneous Surgery, University of Miami, Miami, FL, USA.
authors.forename: Tejas
authors.initials: T
authors.lastname: Patel
authors.affiliation: Department of Dermatology & Cutaneous Surgery, University of Miami, Miami, FL, USA.|Florida Academic Dermatology Centers, Miami, FL, USA.
authors.forename: Francisco A
authors.initials: FA
authors.lastname: Kerdel
mesh_terms: D000230:Adenocarcinoma / Q000150:complications*; D000368:Aged; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000150:complications* / Q000473:pathology / Q000628:therapy; D003879:Dermatologic Agents / Q000627:therapeutic use; D018450:Disease Progression; D000068800:Etanercept / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000556:secondary* / Q000601:surgery; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology*; D009369:Neoplasms / Q000453:epidemiology*; D016609:Neoplasms, Second Primary / Q000150:complications*; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy*; D012307:Risk Factors; D000069549:Ustekinumab / Q000627:therapeutic use
chemical_list: D001688:Biological Products; D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; D000069549:Ustekinumab; D000068800:Etanercept